TY - JOUR
T1 - Treatment of hepatitis C in solid organ transplantation
AU - Chan, Susan E.
AU - Schwartz, Jonathan M.
AU - Rosen, Hugo R.
N1 - Funding Information:
Supported by Veterans Affairs and National Institutes of Health Funding. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.
PY - 2004
Y1 - 2004
N2 - Hepatitis C virus (HCV) infection is highly prevalent worldwide, and results in significant morbidity and mortality. HCV frequently infects haemodialysis patients and appears to impact on long-term survival of kidney transplant recipients. Therefore, treatment is recommended for kidney transplant candidates before transplantation and should be avoided following transplantation because of a high risk of allograft rejection. HCV infection does not appear to influence survival in cardiac transplant recipients and cardiac transplant recipients should also not be treated. In general, HCV-infected patients with cirrhosis are not considered as candidates for either kidney or cardiac transplantation given their risk of decompensation. HCV is the most common indication for liver transplantation and re-infection with varying degrees of liver injury is universal. Survival after liver transplantation is reduced among HCV-infected patients when compared with uninfected controls. Therefore, treatment using interferon and ribavirin is advocated; however, such therapy is frequently limited by adverse effects. Thus, improved antiviral treatment modalities are eagerly awaited in the transplant setting.
AB - Hepatitis C virus (HCV) infection is highly prevalent worldwide, and results in significant morbidity and mortality. HCV frequently infects haemodialysis patients and appears to impact on long-term survival of kidney transplant recipients. Therefore, treatment is recommended for kidney transplant candidates before transplantation and should be avoided following transplantation because of a high risk of allograft rejection. HCV infection does not appear to influence survival in cardiac transplant recipients and cardiac transplant recipients should also not be treated. In general, HCV-infected patients with cirrhosis are not considered as candidates for either kidney or cardiac transplantation given their risk of decompensation. HCV is the most common indication for liver transplantation and re-infection with varying degrees of liver injury is universal. Survival after liver transplantation is reduced among HCV-infected patients when compared with uninfected controls. Therefore, treatment using interferon and ribavirin is advocated; however, such therapy is frequently limited by adverse effects. Thus, improved antiviral treatment modalities are eagerly awaited in the transplant setting.
UR - http://www.scopus.com/inward/record.url?scp=1542721929&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1542721929&partnerID=8YFLogxK
U2 - 10.2165/00003495-200464050-00003
DO - 10.2165/00003495-200464050-00003
M3 - Review article
C2 - 14977386
AN - SCOPUS:1542721929
SN - 0012-6667
VL - 64
SP - 489
EP - 498
JO - Drugs
JF - Drugs
IS - 5
ER -